Psychiatry · IPS

Schizophrenia

IPS

Source:Indian Psychiatric Society Clinical Practice Guidelines for Management of Schizophrenia (2017, refreshed)NICE CG178 (2022)Maudsley Prescribing Guidelines (2022)

Verified Apr 2026

Ask House about this guideline

Red Flags

Active suicidality, command auditory hallucinations to harm self/others, severe agitation, or violence — admit; same-day psychiatric assessment under appropriate legal framework^[1]
Catatonia (mutism, posturing, stupor, waxy flexibility) — emergency benzodiazepine challenge (lorazepam); rule out medical causes; consider ECT^[1]
Neuroleptic malignant syndrome (rigidity, fever, autonomic instability, raised CK) — stop antipsychotic; admit to ITU; supportive care, dantrolene/bromocriptine^[1]
First-episode psychosis with neurological signs, atypical features, or onset >40 years — neuroimaging and exclude organic cause (autoimmune encephalitis, metabolic, drug-induced)^[1]

First-line treatment

Interventions

Shared decision making and care plan^[1]
Engage patient and family/carer in treatment plan; recovery-oriented goals; written care plan covering medication, therapy, social support, crisis planning; respect autonomy within safety constraints
Coordinated specialist early intervention service for FEP^[1]
Early intervention reduces relapse and improves outcomes; multidisciplinary team (psychiatrist, CPN, psychologist, social worker, OT, peer support); family intervention
Psychosocial interventions alongside medication^[1]
Cognitive behavioural therapy for psychosis (CBTp), family intervention, supported employment, social skills training, exercise; treat comorbid substance use; address smoking
Annual physical health monitoring^[1]
Schizophrenia confers 15–20 year mortality gap, mostly cardiovascular and metabolic. Monitor weight, BP, glucose, lipids, smoking; primary-care led management of cardiovascular risk

First-line drug therapy

Drug	Class	Adult	Paediatric	Notes
Olanzapine^[1]	Atypical antipsychotic	5–20 mg PO daily; first-episode start 5 mg	—	Effective broad-spectrum; weight gain and metabolic syndrome are major concerns; sedating; useful in agitated patients; metabolic monitoring
Risperidone^[1]	Atypical antipsychotic	1–6 mg PO daily; first-episode start 1–2 mg	Adolescents per local protocol	Effective, lower metabolic burden than olanzapine; hyperprolactinaemia; long-acting injectable available for adherence
Aripiprazole^[1]	Atypical antipsychotic / partial dopamine agonist	10–30 mg PO daily; first-episode start 10 mg	—	Lower metabolic burden, lower prolactin elevation; activating — initial restlessness; long-acting injectable available
Haloperidol (typical)^[1]	Typical antipsychotic	2–20 mg PO daily; acute IM 2.5–5 mg	—	Effective but extrapyramidal side effects, tardive dyskinesia; widely available and cost-effective; ECG monitoring at higher doses
Clozapine (treatment-resistant)^[1]	Atypical antipsychotic	12.5 mg PO night start, titrate slowly to 200–450 mg/day; specialist clozapine clinic	—	Treatment-resistant schizophrenia (failure of ≥2 adequate antipsychotic trials); haematological monitoring (agranulocytosis); sedation, hypersalivation, weight gain, myocarditis screen, constipation; only on specialist registry
Long-acting injectable antipsychotic^[1]	Depot antipsychotic	Risperidone LAI 25–50 mg IM every 2 weeks; aripiprazole 400 mg IM monthly; paliperidone palmitate 100–150 mg IM monthly; haloperidol decanoate 50–200 mg IM monthly	—	Adherence-related relapse; offer at any stage; assess oral tolerability first; bridging oral cover during initiation per agent

Olanzapine^[1]

Atypical antipsychotic

Adult: 5–20 mg PO daily; first-episode start 5 mg
Paediatric: —

Effective broad-spectrum; weight gain and metabolic syndrome are major concerns; sedating; useful in agitated patients; metabolic monitoring

Risperidone^[1]

Atypical antipsychotic

Adult: 1–6 mg PO daily; first-episode start 1–2 mg
Paediatric: Adolescents per local protocol

Effective, lower metabolic burden than olanzapine; hyperprolactinaemia; long-acting injectable available for adherence

Aripiprazole^[1]

Atypical antipsychotic / partial dopamine agonist

Adult: 10–30 mg PO daily; first-episode start 10 mg
Paediatric: —

Lower metabolic burden, lower prolactin elevation; activating — initial restlessness; long-acting injectable available

Haloperidol (typical)^[1]

Typical antipsychotic

Adult: 2–20 mg PO daily; acute IM 2.5–5 mg
Paediatric: —

Effective but extrapyramidal side effects, tardive dyskinesia; widely available and cost-effective; ECG monitoring at higher doses

Clozapine (treatment-resistant)^[1]

Atypical antipsychotic

Adult: 12.5 mg PO night start, titrate slowly to 200–450 mg/day; specialist clozapine clinic
Paediatric: —

Treatment-resistant schizophrenia (failure of ≥2 adequate antipsychotic trials); haematological monitoring (agranulocytosis); sedation, hypersalivation, weight gain, myocarditis screen, constipation; only on specialist registry

Long-acting injectable antipsychotic^[1]

Depot antipsychotic

Adult: Risperidone LAI 25–50 mg IM every 2 weeks; aripiprazole 400 mg IM monthly; paliperidone palmitate 100–150 mg IM monthly; haloperidol decanoate 50–200 mg IM monthly
Paediatric: —

Adherence-related relapse; offer at any stage; assess oral tolerability first; bridging oral cover during initiation per agent

Safety-net

Take medication every day as prescribed; missing doses is the commonest cause of relapse — long-acting injection is an option if remembering daily is difficult^[1]
Tell your prescriber about new symptoms (stiffness, restlessness, tremor, muscle pain, sudden fever, rapid weight gain, loss of menstrual periods) — manageable with adjustment^[1]
Smoking cessation, dietary advice, and exercise reduce the cardiovascular gap; offer help with these alongside medication^[1]

Referral criteria

All first-episode psychosisEarly intervention in psychosis service / community mental health team^[1]
Treatment-resistant schizophrenia (failure of ≥2 antipsychotics at adequate dose and duration)Specialist clozapine clinic^[1]
Acute risk to self or others, severe agitation, catatonia, or NMSEmergency department; admission under appropriate legal framework^[1]
Pregnancy or planning pregnancy on antipsychoticPerinatal mental health and obstetric clinic^[1]

Clinical summary

Diagnosis and pharmacological + psychosocial management of schizophrenia, including first-episode psychosis and treatment-resistant illness.

References

1.Indian Psychiatric Society Clinical Practice Guidelines for Management of Schizophrenia (2017, refreshed); NICE CG178; Maudsley Prescribing Guidelines (2022)

Drug

Class

Adult

Paediatric

Notes

Olanzapine^[1]

Atypical antipsychotic

5–20 mg PO daily; first-episode start 5 mg

—

Effective broad-spectrum; weight gain and metabolic syndrome are major concerns; sedating; useful in agitated patients; metabolic monitoring

Risperidone^[1]

Atypical antipsychotic

1–6 mg PO daily; first-episode start 1–2 mg

Adolescents per local protocol

Effective, lower metabolic burden than olanzapine; hyperprolactinaemia; long-acting injectable available for adherence

Aripiprazole^[1]

Atypical antipsychotic / partial dopamine agonist

10–30 mg PO daily; first-episode start 10 mg

—

Lower metabolic burden, lower prolactin elevation; activating — initial restlessness; long-acting injectable available

Haloperidol (typical)^[1]

Typical antipsychotic

2–20 mg PO daily; acute IM 2.5–5 mg

—

Effective but extrapyramidal side effects, tardive dyskinesia; widely available and cost-effective; ECG monitoring at higher doses

Clozapine (treatment-resistant)^[1]

Atypical antipsychotic

12.5 mg PO night start, titrate slowly to 200–450 mg/day; specialist clozapine clinic

—

Long-acting injectable antipsychotic^[1]

Depot antipsychotic

Risperidone LAI 25–50 mg IM every 2 weeks; aripiprazole 400 mg IM monthly; paliperidone palmitate 100–150 mg IM monthly; haloperidol decanoate 50–200 mg IM monthly

—

Adherence-related relapse; offer at any stage; assess oral tolerability first; bridging oral cover during initiation per agent